PMID- 28477247
OWN - NLM
STAT- MEDLINE
DCOM- 20180417
LR  - 20240204
IS  - 1878-7479 (Electronic)
IS  - 1933-7213 (Print)
IS  - 1878-7479 (Linking)
VI  - 14
IP  - 3
DP  - 2017 Jul
TI  - Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's 
      Perspective.
PG  - 741-749
LID - 10.1007/s13311-017-0531-1 [doi]
AB  - Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine 
      (MDMA) has had a well-known history as the recreationally used drug ecstasy. What 
      is less well known by the public is that MDMA started its life as a therapeutic 
      agent and that in recent years an increasing amount of clinical research has been 
      undertaken to revisit the drug's medical potential. MDMA has unique 
      pharmacological properties that translate well to its proposed agent to assist 
      trauma-focused psychotherapy. Psychological trauma-especially that which arises 
      early in life from child abuse-underpins many chronic adult mental disorders, 
      including addictions. Several studies of recent years have investigated the 
      potential role of MDMA-assisted psychotherapy as a treatment for post-traumatic 
      stress disorder, with ongoing plans to see MDMA therapy licensed and approved 
      within the next 5 years. Issues of safety and controversy frequently surround 
      this research, owing to MDMA's often negative media-driven bias. However, 
      accurate examination of the relative risks and benefits of clinical MDMA-in 
      contrast to the recreational use of ecstasy-must be considered when assessing its 
      potential benefits and the merits of future research. In this review, the author 
      describes these potential benefits and explores the relatives risks of 
      MDMA-assisted psychotherapy in the context of his experience as a child and 
      adolescent psychiatrist, having seen the relative limitations of current 
      pharmacotherapies and psychotherapies for treating complex post-traumatic stress 
      disorder arising from child abuse.
FAU - Sessa, Ben
AU  - Sessa B
AD  - Psychopharmacology Department, Department of Medicine, Imperial College London 
      University, Burlington Danes Building, 160 Du Cane Road, London, W12 0NN, UK. 
      b.sessa@imperial.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurotherapeutics
JT  - Neurotherapeutics : the journal of the American Society for Experimental 
      NeuroTherapeutics
JID - 101290381
RN  - 0 (Serotonin Agents)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child Abuse/psychology
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*therapeutic use
MH  - Psychiatry/methods
MH  - Serotonin Agents/*therapeutic use
MH  - Stress Disorders, Post-Traumatic/*drug therapy/etiology
PMC - PMC5509627
OTO - NOTNLM
OT  - MDMA
OT  - PTSD
OT  - Psychedelics
OT  - Psychotherapy
OT  - Trauma
OT  - addictions
EDAT- 2017/05/10 06:00
MHDA- 2018/04/18 06:00
PMCR- 2017/05/05
CRDT- 2017/05/07 06:00
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/04/18 06:00 [medline]
PHST- 2017/05/07 06:00 [entrez]
PHST- 2017/05/05 00:00 [pmc-release]
AID - S1878-7479(23)01452-6 [pii]
AID - 531 [pii]
AID - 10.1007/s13311-017-0531-1 [doi]
PST - ppublish
SO  - Neurotherapeutics. 2017 Jul;14(3):741-749. doi: 10.1007/s13311-017-0531-1.